Sumatriptan inhibition of N-type calcium channel mediated signaling in dural CGRP terminal fibres

Abstract

The selective 5-HT1 receptor agonist sumatriptan is an effective therapeutic for migraine pain yet the antimigraine mechanisms of action remain controversial. Pain-responsive fibres containing calcitonin gene-related peptide (CGRP) densely innervating the cranial dura mater are widely believed to be an essential anatomical substrate for the development of migraine pain. 5HT1 receptors in the dura colocalize with CGRP fibres in high density and thus provide a possible peripheral site of action for sumatriptan. In the present study, we used high-resolution optical imaging selectively within individual mouse dural CGRP nociceptive fibre terminations and found that application of sumatriptan caused a rapid, reversible dose-dependent inhibition in the amplitude of single action potential evoked Ca2+ transients. Pre-application of the 5-HT1 antagonist GR127935 or the selective 5-HT1D antagonist BRL 15572 prevented inhibition while the selective 5-HT1B antagonist SB 224289 did not, suggesting this effect was mediated selectively through the 5-HT1D receptor subtype. Sumatriptan inhibition of the action potential evoked Ca2+ signaling was mediated selectively through N-type Ca2+ channels. Although the T-type Ca2+ channel accounted for a greater proportion of the Ca2+ signal it did not mediate any of the sumatriptan inhibition. Our findings support a peripheral site of action for sumatriptan in inhibiting the activity of dural pain fibres selectively through a single Ca2+ channel subtype. This finding adds to our understanding of the mechanisms that underlie the clinical effectiveness of 5HT1 receptor agonists such as sumatriptan and may provide insight for the development of novel peripherally targeted therapeutics for mitigating the pain of migraine.

Serotonin, 5HT1 agonists, and migraine

“…Sumatriptan was found to modulate ionic currents in dural-projecting trigeminal neurons in vitro including voltage-gated calcium currents (confirming an earlier report [32]) and now demonstrating modulation of potassium currents [33*]. This drug also inhibited calcium influx in individual neuronal fibers in the dura via calcium channel modulation [34]. Sumatriptan was found to inhibit the capsaicin/noxious heat/proton-sensitive transient receptor potential channel vanilloid 1 (TRPV1) in trigeminal neurons [35*], consistent with other reports where sumatriptan inhibited both cytokine production in response to capsaicin [36] and capsaicin-induced CGRP release from trigeminal neurons [37].…”

Efficacy of (S)-lacosamide in preclinical models of cephalic pain

“…CaV2.2 activity has been shown to trigger CGRP release [3; 34]. Since CaV2.2 activity is dependent on CRMP2 expression [9; 15], we determined if CRMP2 and CaV2.2 were expressed within the same regions of TGs.…”

Sumatriptan, an Antimigraine Drug, Inhibits Pentylenetetrazol-induced Seizures in NMRI Mice

“…Eliminating or reducing the brain serotonin levels may increase seizures in epilepsy-prone rats [39,40]. Recently, the inhibitory effects of sumatriptan on N-type calcium channels have been reported [41]. N-type calcium channel antagonists have an inhibitory effect on amygdala kindling [42].…”